Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0497406 (overweight)
 26,365 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Obesity is increasing rapidly among women all over the world, and more women in fertile ages become overweight and obese. Among all other problems, women who are obese have higher rates of amenorrhoea and infertility. Obese women have a higher risk of complications during pregnancy such as hypertensive diagnoses and gestational diabetes, and delivery complications such as higher rates of caesarean sections and prolonged time of delivery. The aim of this article is to review the consequences of being obese during the reproductive life of a woman.
 ...
PMID:Effects of obesity on women's reproduction and complications during pregnancy. 1524 82

The epidemic of obesity has highlighted the extent of the risks associated with this disease. The risks arise from the increased mass of fat tissue, as well as the products produced by the increased number and size of fat cells in obese individuals. Psychosocial dysfunction, obstructive sleep apnea, and osteoarthritis can be a direct result of increased fat mass. Other diseases associated with obesity result from the metabolic consequences of enlarged fat cells. Diabetes, gallbladder stones, high blood pressure, liver disease, coronary artery disease, cerebrovascular disease, certain types of cancers, and infertility can all be traced in part to the increased secretion of inflammatory and coagulation molecules from fat cells. Finally, obesity also increases overall mortality. It is clear from this review that the morbidity and increased mortality of overweight and obesity is substantial and should prompt further attention towards the need for appropriate weight management in health care.
 ...
PMID:Obesity related morbidity and mortality. 1575 9

Body mass index (BMI) should be assessed at every health care visit. Overweight and obesity are associated with higher risks of hypertension, type 2 diabetes, irregular ovulation, infertility, and pregnancy and birth complications. Family planning and annual gynecology examinations give primary care providers the opportunity to share basic weight management guidelines with women. Weight management to normalize BMI or reduce overweight and obesity is vital to reduce future comorbidities. This article demonstrates integration of basic weight management into gynecologic care.
 ...
PMID:Weight management in gynecologic care. 1615 72

The young specialty of reproductive medicine has developed tremendously in barely 30 years and has taken a prominent place in the field of obstetrics and gynaecology. In addition to the diagnosis and treatment of infertility, reproductive medicine comprises a large number of medical activities, most of which affect women in almost all phases of life, from shortly after puberty to old age. A key role is played by the pathophysiology of ovarian function and ovarian hormones. Requests for medical assistance concern: disorders of sexual development, the consequences for health in the short- and long-term of overweight and anovulation early in life, premature menopause and the need for hormone replacement, damage to the ovaries as a result of radio- or chemotherapy for cancer, the hormonal aspects of breast cancer, the hormonal aspects of sexuality and well-being, and counselling regarding contraception or menopausal symptoms and hormone replacement.
 ...
PMID:[Reproductive medicine: more than the diagnosis and treatment of infertility]. 1632 Jun 75

The purpose of this prospective cohort study of twins and triplets was to evaluate perinatal and early childhood outcomes through 18 months of age. The study population included 141 twin pregnancies (282 twin children) and 8 triplet pregnancies (24 triplet children) recruited between May, 1996 and June, 2001. Mothers of triplets versus twins were significantly more likely to have infertility treatments, to be overweight or obese before conception, to be admitted antenatally, and to deliver by cesarean section. Length of gestation for triplets was significantly shorter (-2.31 weeks, p < .0001), and more likely to be less than 35 weeks (Adjusted Odds Ratio [AOR] 9.38, 95% confidence interval [CI] 3.22-27.29). Average birthweight for triplets was significantly lighter (-495 grams, p < .0001), and more likely to be low birthweight (AOR 11.38, 95% CI 3.11-41.61). Triplets were also more likely to be admitted to neonatal intensive care (AOR 7.97, 95% CI 2.13-29.77), to require mechanical ventilation (AOR 5.67, 95% CI 2.05-15.65), to develop respiratory distress syndrome (AOR 12.50, 95% CI 3.89-40.20), or a major morbidity (retinopathy of prematurity, necrotizing enterocolitis, ventilator support, or grade III or IV intraventricular hemorrhage, AOR 5.67, 95% CI 2.05-15.65). Weight, length, and head circumference was significantly smaller at birth for triplets compared to twins, and these differences remained through 18 months of age, along with lower mental developmental scores at the oldest age. Compared to twins, triplets have greater neonatal morbidity, and through 18 months of age lower mental and motor scores, slower postnatal growth and more residual stunting, particularly of length and head circumference.
 ...
PMID:Perinatal and early childhood outcomes of twins versus triplets. 1661 72

Current data supporting the effectiveness of metformin as a fertility treatment for women with polycystic ovary syndrome have been misinterpreted. Still unproven for women with polycystic ovary syndrome is, first, whether metformin adds to the standard first-line fertility management in all women, second, whether metformin is an effective fertility treatment for overweight women, and third, the relative fertility efficacy of metformin and clomiphene citrate as a first-line treatment in women with a lower body weight. The PCOSMIC (polycystic ovary syndrome: metformin for infertility with clomiphene) trial is an ongoing New Zealand multicentre double-blind placebo-controlled parallel randomised trial assessing these questions.
 ...
PMID:No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. 1663 37

Body weight, and its constituent components of fat mass and lean tissue, plays an important role modulating reproductive development and functioning. Body weight influences the timing of menarche and the capacity to achieve a pregnancy. The nature of this relationship appears to be some variant on a 'U' shape. Extremes in body weight are associated with infertility and a range of adverse outcomes for both mother and baby across the course of pregnancy and perinatal period. Whereas underweight is associated with poor fetal growth and elevated pregnancy loss, overweight is more strongly associated with diseases in pregnancy, pregnancy loss and stillbirth and high birth weight. An emerging area of interest is the role of obesity on fertility, and the intergenerational 'tracking' of high maternal body weight into the second and subsequent generations, resulting not only in an increased risk of metabolic disease, but also perturbed reproductive functioning in the offspring.
 ...
PMID:Evidence for effects of weight on reproduction in women. 1679 98

Significant increase of obesity prevalence in almost all countries in the world recently has had obesity as a global health problem, and WHO in 1998 defined it as "the global epidemic". Simply, obesity is defined as an excessive fat accumulation in fat tissue due to imbalance of energy intake and expenditure. Body mass index is a simple method for defining the degree of overweight and obesity, however, waist circumference is the preferred measure of abdominal obesity because it has greater relationship with the risk of metabolic and cardiovascular diseases. Body fatness reflects the interactions of development, environment and genetic factors. The role of genetic factors has already existed, nevertheless, environment factors are likely more important in developing obesity. Increased mortality among the obese is evident for several life-threatening diseases including type 2 diabetes, cardiovascular disease, gallbladder disease, and hormone-sensitive and gastrointestinal cancers. Risks are also higher for some non-fatal conditions such as back pain, arthritis, infertility and, in many westernized countries, poor psychosocial functioning. Obesity is not only threatening health, also impacts on high economic and social cost. Effective prevention of obesity should be focused to high risk individuals or groups. Individuals who have some existing weight-related problems and those with a high risk of developing obesity co-morbidity such as cardiovascular disease and type 2 diabetes should be a key priority in this prevention strategy. Although weight loss in obese persons of any age can improve obesity-related medical complications, physical function, and quality of life, the primary purpose for weigh-loss therapy may differ across age group. The current therapeutic tools available for weight management are: (1) lifestyle intervention involving diet, physical activity, and behavior modification; (2) pharmacotherapy; and (3) surgery. Moderate weight loss (5-10% of initial weight) by any programs is a realistic target in management of obesity associated with improvement of risk factors of metabolic and cardiovascular diseases.
 ...
PMID:Update in the management of obesity. 1713 90

Polycystic ovary syndrome affects 6%-7% of reproductive-aged women, making it the most common endocrine disorder in this population. It is characterized by chronic anovulation and hyperandrogenism. Affected women may present with reproductive manifestations such as irregular menses or infertility, or cutaneous manifestations, including hirsutism, acne, or male-pattern hair loss. Over the past decade, several serious metabolic complications also have been associated with polycystic ovary syndrome including type 2 diabetes mellitus, metabolic syndrome, sleep apnea, and possibly cardiovascular disease and nonalcoholic fatty liver disease. In addition to treating symptoms by regulating menstrual cycles and improving hyperandrogenism, it is imperative that clinicians recognize and treat metabolic complications. Lifestyle therapies are first-line treatment in women with polycystic ovary syndrome, particularly if they are overweight. Pharmacological therapies are also available and should be tailored on an individual basis. This article reviews the diagnosis, clinical manifestations, metabolic complications, and treatment of the syndrome. A table summarizing treatment recommendations is provided.
 ...
PMID:Polycystic ovary syndrome: diagnosis and treatment. 1727 49

Ovulation induction is the principal infertility treatment for women with polycystic ovarian syndrome (PCOS). Among PCOS patients who are overweight or obese, weight loss is the most physiologic method of inducing ovulation. For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction. In clomiphene-resistant women, alternative treatments include adjunctive metformin or dexamethasone, aromatase inhibitors, or ovarian drilling. If there is no pregnancy despite several cycles of successful ovulation induction, gonadotropin treatment should be considered, in which case in vitro fertilization is recommended as the safest and most effective strategy.
 ...
PMID:Ovulation induction management of PCOS. 1730 40


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>